Mastering allogeneic NK cell therapies: flexibility, robustness, and speed to clinic

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Natural killer (NK) cells play a critical role in the body's immune system. Their unique ability to identify and destroy abnormal cells, while leaving healthy cells unharmed, make them a promising treatment option for various cancers and infectious diseases. NK and CAR-NK cells represent an attractive alternate modality with the potential to address shortcomings experienced by T cell and CAR-T-based therapies. NK cell therapies also offer impressive feasibility as an off-the-shelf product, an enhanced safety profile with respect to cytokine release syndrome, neurotoxicity, and graft-versus-host disease, and renewed promise where T cells have fallen short in the solid tumor setting.

As a dedicated cell and gene therapy CDMO, OmniaBio is at the forefront of manufacturing innovation, providing robust technology platforms to propel the industry’s advancement. In the upcoming webinar, we will explore the challenges and opportunities of NK cell therapy development, complemented by a captivating case study highlighting our NK cell therapy platform. The case study will provide valuable insights supported by relevant data for NK cell expansion, NK cell transduction efficiency optimization enabling genetic customization, scale-up to clinically relevant quantities, and key NK analytics and functional assays.

• Discuss industry challenges and opportunities around NK cell therapy development and robust manufacturing preparation and infrastructure
• Explore new, customizable, and scalable manufacturing platforms for NK cell therapies
• Share an NK cell therapy platform case study and supporting data that can be applied in process development to streamline time to clinic, while mitigating challenges in manufacturing at commercial scale

Tey Irrazabal

Lead Scientist I at CCRM | OmniaBio, Inc

Tey Irrazabal did both a bachelor and a master in Biochemistry at the University of Chile. During her Master thesis, Tey worked developing and testing adenoviral vectors for gene therapy. Before moving to Canada, she worked designing and producing adeno-associated viral vectors for genetic engineering in various neurodegenerative models. Tey obtained a PhD in Immunology at the University of Toronto, while studying the effects of diet-derived metabolites and inflammation on cancer progression. After two postdoctoral fellowships where she participated in two clinical trials in collaboration with the Sunnybrook and Mount Sinai Hospitals, she joined CCRM, where she works closely with the OmniaBio PD team to apply her 14 years of research experience in genetic engineering and immunology to develop robust immune cell therapy platform processes that OmniaBio can offer to benefit therapeutic sponsors.

Watch now

SPEAKERS

Tey Irrazabal

Lead Scientist I at CCRM | OmniaBio, Inc

You might also like

Large-scale manufacturing of allogeneic stem cell-derived NK cell therapies

Monica Raimo, Jan Spanholtz

6 August

Watch

Enabling allogeneic cell therapy development: scaling up generation of PSC-derived NK cells

Mark Kennedy, Marcus Bunn

15 October

Watch

Clinical-scale non-viral gene edited CAR-NK cells for cell therapy

Krishanu Saha, Namritha Ravinder

18 September

Watch

Optimizing access to high quality, standardized, and compliant leukopaks for the development and commercialization of allogeneic therapies

Makensie Becker

18 April

Watch